Cargando…
A novel cancer immunotherapy based on the combination of a synthetic carbohydrate-pulsed dendritic cell vaccine and glycoengineered cancer cells
Immune tolerance to tumor-associated carbohydrate antigens (TACAs) has severely restricted the usefulness of most TACAs. To overcome this problem, we selected a sialylated trisaccharide TACA, GM3, as a target antigen, and tested a new immunotherapeutic strategy by combining metabolic bioengineering...
Autores principales: | Qiu, Lei, Li, Jie, Yu, Shichong, Wang, Qianli, Li, Yinghua, Hu, Zhenlin, Wu, Qiuye, Guo, Zhongwu, Zhang, Junping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467142/ https://www.ncbi.nlm.nih.gov/pubmed/25760071 |
Ejemplares similares
-
Erratum: A novel cancer immunotherapy based on the combination of a synthetic carbohydrate-pulsed dendritic cell vaccine and glycoengineered cancer cells
por: Qiu, Lei, et al.
Publicado: (2015) -
Glycoengineering of Natural Killer Cells with CD22
Ligands for Enhanced Anticancer Immunotherapy
por: Wang, Xianwu, et al.
Publicado: (2020) -
Genetic glycoengineering in mammalian cells
por: Narimatsu, Yoshiki, et al.
Publicado: (2021) -
The Applications of Metabolic Glycoengineering
por: Ying, Liwei, et al.
Publicado: (2022) -
Plasmacytoid Dendritic Cells and Cancer Immunotherapy
por: Fu, Chunmei, et al.
Publicado: (2022)